Citigroup Upgrades Haemonetics to Buy, Raises Price Target to $123

Benzinga Newsdesk www.benzinga.com Positive 88.8%

Neg 0% Neu 0% Pos 88.8%

Citigroup analyst Joanne Wuensch upgrades Haemonetics (NYSE:HAE) from Neutral to Buy and raises the price target from $92 to $123.